Biopharma | May 06, 2026
Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
Report highlights growing confidence in digitalisation and AI, even as healthcare leaders remain concerned about workforce gaps, cybersecurity, and data readiness
Doctors highlight rising respiratory risks linked to pollution, seasonal changes, and poor treatment adherence amid increasing asthma burden in India
Discussions focused on digital health, non-communicable diseases, resilient supply chains, medical innovation, and healthcare workforce development
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
Subscribe To Our Newsletter & Stay Updated
